Payment overview · 2025
General Payments
$1,335.87
82 reported records · 18 companies
Healthcare provider profile · identity verified
Robert O Spruill, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOULTRIE, GA · NPI 1609808179
Verified facts
What the public records show
CMS Open Payments records show Robert O Spruill, MD received $1,335.87 in general payments during 2025 across 82 reported records.
ABBVIE INC. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 722 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $356.37 | 26.7% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $219.81 | 16.4% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.09 | 13.9% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $161.58 | 12.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.20 | 5.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.90 | 3.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.27 | 3.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.53 | 2.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.79 | 2.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.45 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.20 | 1.7% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $21.61 | 1.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.20 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.12 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.71 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.44 | 1.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.08 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.52 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,335.87 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $235.63 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.22 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $131.40 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.12 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $112.64 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.14 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $73.84 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $55.58 | 4 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $52.38 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.90 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.90 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.90 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.27 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.20 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.46 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $6.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $6.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 722 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 155 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 81 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 147 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 21 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
153 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
155 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
147 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
233 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
722 | 101 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 2017 | 290 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1854 | 346 |
| Gabapentin | Gabapentin | 1648 | 221 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1270 | 219 |
| Potassium Chloride | Potassium Chloride | 1051 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 1005 | 163 |
| Famotidine | Famotidine | 989 | 105 |
| Furosemide | Furosemide | 849 | 129 |
| Pravastatin Sodium | Pravastatin Sodium | 830 | 113 |
| Lisinopril | Lisinopril | 810 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 794 | 164 |
| Eliquis | Apixaban | 722 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 695 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 692 | 153 |
| Metoprolol Tartrate | Metoprolol Tartrate | 652 | 80 |
| Trazodone Hcl | Trazodone Hcl | 650 | 63 |
| Metformin Hcl | Metformin Hcl | 579 | 104 |
| Carvedilol | Carvedilol | 562 | 68 |
| Sertraline Hcl | Sertraline Hcl | 547 | 71 |
| Montelukast Sodium | Montelukast Sodium | 495 | 74 |
| Mirtazapine | Mirtazapine | 480 | 54 |
| Valsartan | Valsartan | 479 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 477 | 65 |
| Allopurinol | Allopurinol | 474 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 454 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 444 | 60 |
| Donepezil Hcl | Donepezil Hcl | 443 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 416 | 40 |
| Buspirone Hcl | Buspirone Hcl | 410 | 47 |
| Losartan Potassium | Losartan Potassium | 394 | 92 |
| Hydralazine Hcl | Hydralazine Hcl | 378 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 372 | 99 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 361 | 42 |
| Nifedipine Er | Nifedipine | 338 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 334 | 99 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 292 | 66 |
| Meloxicam | Meloxicam | 292 | 70 |
| Memantine Hcl | Memantine Hcl | 289 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 281 | 107 |
| Jardiance | Empagliflozin | 262 | 61 |
| Sucralfate | Sucralfate | 262 | 48 |
| Levetiracetam | Levetiracetam | 260 | 26 |
| Tramadol Hcl | Tramadol Hcl | 260 | 86 |
| Primidone | Primidone | 259 | 16 |
| Divalproex Sodium | Divalproex Sodium | 251 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 52 |
| Xarelto | Rivaroxaban | 235 | 29 |
| Entresto | Sacubitril/Valsartan | 233 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 233 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 108 |
| Citalopram Hbr | Citalopram Hydrobromide | 223 | 38 |
| Alprazolam | Alprazolam | 215 | 57 |
| Atenolol | Atenolol | 200 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 200 | 34 |
| Bumetanide | Bumetanide | 198 | 32 |
| Simvastatin | Simvastatin | 196 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 27 |
| Olanzapine | Olanzapine | 191 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 188 | 17 |
| Finasteride | Finasteride | 187 | 19 |
| Bupropion Xl | Bupropion Hcl | 184 | 33 |
| Midodrine Hcl | Midodrine Hcl | 183 | 26 |
| Clonazepam | Clonazepam | 174 | 33 |
| Torsemide | Torsemide | 171 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 169 | 59 |
| Ondansetron Hcl | Ondansetron Hcl | 161 | 79 |
| Farxiga | Dapagliflozin Propanediol | 155 | 19 |
| Myrbetriq | Mirabegron | 153 | 18 |
| Pregabalin | Pregabalin | 152 | 44 |
| Amiodarone Hcl | Amiodarone Hcl | 149 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 149 | 20 |
| Ezetimibe | Ezetimibe | 149 | 34 |
| Mounjaro | Tirzepatide | 147 | 24 |
| Baclofen | Baclofen | 145 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 134 | suppressed |
| Tradjenta | Linagliptin | 132 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 131 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 40 |
| Ranolazine Er | Ranolazine | 126 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 122 | 71 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 122 | 16 |
| Spironolactone | Spironolactone | 113 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 25 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 100 | 84 |
| Topiramate | Topiramate | 96 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 90 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 88 | 62 |
| Lactulose | Lactulose | 83 | 37 |
| Aripiprazole | Aripiprazole | 81 | 18 |
| Linzess | Linaclotide | 81 | 26 |
| Propranolol Hcl | Propranolol Hcl | 80 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | suppressed |
| Celecoxib | Celecoxib | 78 | suppressed |
| Mupirocin | Mupirocin | 78 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 77 | suppressed |
| Prednisone | Prednisone | 75 | 28 |
| Risperidone | Risperidone | 74 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 18 |
| Lorazepam | Lorazepam | 72 | 25 |
| Meclizine Hcl | Meclizine Hcl | 71 | 34 |
| Chlorthalidone | Chlorthalidone | 69 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | suppressed |
| Synthroid | Levothyroxine Sodium | 69 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | 16 |
| Fluconazole | Fluconazole | 67 | 44 |
| Rexulti | Brexpiprazole | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 65 | 11 |
| Nystatin | Nystatin | 65 | 40 |
| Temazepam | Temazepam | 65 | suppressed |
| Brilinta | Ticagrelor | 63 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 63 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 63 | suppressed |
| Movantik | Naloxegol Oxalate | 63 | suppressed |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 61 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 50 |
| Levemir Flexpen | Insulin Detemir | 59 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | suppressed |
| Lubiprostone | Lubiprostone | 57 | suppressed |
| Amoxicillin | Amoxicillin | 56 | 46 |
| Megestrol Acetate | Megestrol Acetate | 56 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 55 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 53 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 15 |
| Gemtesa | Vibegron | 52 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 51 | suppressed |
| Azithromycin | Azithromycin | 50 | 42 |
| Glipizide | Glipizide | 50 | 11 |
| Estradiol | Estradiol | 49 | 13 |
| Latanoprost | Latanoprost | 49 | 23 |
| Ondansetron Odt | Ondansetron | 49 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 49 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 11 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 47 | 28 |
| Metformin Hcl Er | Metformin Hcl | 47 | 12 |
| Desmopressin Acetate | Desmopressin Acetate | 46 | suppressed |
| Levemir | Insulin Detemir | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 39 |
| Nyamyc | Nystatin | 45 | 28 |
| Roflumilast | Roflumilast | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Carbamazepine Er | Carbamazepine | 43 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 43 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 41 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Ozempic | Semaglutide | 39 | 21 |
| Levofloxacin | Levofloxacin | 38 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 27 |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Thioridazine Hcl | Thioridazine Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 17 |
| Glimepiride | Glimepiride | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 30 |
| Nitroglycerin | Nitroglycerin | 35 | 29 |
| Albuterol Sulfate | Albuterol Sulfate | 34 | 24 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 34 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Leflunomide | Leflunomide | 33 | suppressed |
| Felodipine Er | Felodipine | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 31 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | 13 |
| Cephalexin | Cephalexin | 29 | 18 |
| Colchicine | Colchicine | 29 | 18 |
| Corlanor | Ivabradine Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Budesonide | Budesonide | 28 | suppressed |
| Calcium Acetate | Calcium Acetate | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 12 |
| Methocarbamol | Methocarbamol | 27 | 18 |
| Nystop | Nystatin | 27 | 22 |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Mirabegron Er | Mirabegron | 25 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 24 |
| Folic Acid | Folic Acid | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | 15 |
| Cefdinir | Cefdinir | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 12 |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Ertapenem | Ertapenem Sodium | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Aztreonam | Aztreonam | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 11 |
| Indapamide | Indapamide | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,335.87 · 82 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Azstarys, BEXSERO, CREON, ELIQUIS, EVENITY, FARXIGA, Jornay PM, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error